FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991002006> ?p ?o ?g. }

• W1991002006 endingPage "425" @default.
• W1991002006 startingPage "414" @default.
• W1991002006 abstract "The topoisomerase II inhibitor, VP-16 (etoposide), is an important component in many chemotherapeutic regimens. To characterize resistance to this drug, the human melanoma cell line, FEM-X, was selected in multiple steps with VP-16. To prevent the development of typical multidrug resistance, an inhibitor of P-glycoprotein, the tiapamil analog, RO-11-2933, was added to the selections. The resultant clone FVP3 is 56-fold resistant to VP-16 and cross-resistant to doxorubicin (Adriamycin) (9-fold) and VM-26 (27-fold). These cells are also two- to four-fold resistant to m-AMSA, daunorubicin, and mitoxantrone. FVP3 is not resistant to the P-glycoprotein substrates vinblastine, does not express the MDR1 gene at detectable levels, and does not show reduced 3H-VP-16 accumulation. Unlike other cell lines that exhibit resistance to inhibitors of topoisomerase II, FVP3 has the same level of topoisomerase II expression and activity as FEM-X. Using live cells treated with VP-16, band depletion assays and KCI/SDS precipitation assays show that topoisomerase II from FVP3 is much less susceptible to drug-induced cleavable complex formation than is that from FEM-X. This difference in sensitivity to VP-16 is also detected using lysates from disrupted cells, but not with isolated nuclei devoid of cytoplasmic and membrane components. In addition, the topoisomerase II present in nuclear extracts from FVP3 is not resistant to the effects of VP-16 as measured by: (1) inhibition of strand passing activity during decatenation of kinetoplast DNA, (2) drug-induced linearization of plasmid DNA, and (3) immunodepletion by VP-16. These results suggest that some component of the cytoplasm or cellular membranes, or a factor depleted from nuclei during their isolation, is responsible for the resistance to VP-16 in FVP3." @default.
• W1991002006 created "2016-06-24" @default.
• W1991002006 creator A5004950254 @default.
• W1991002006 creator A5008349599 @default.
• W1991002006 creator A5030334751 @default.
• W1991002006 creator A5053438858 @default.
• W1991002006 creator A5056573254 @default.
• W1991002006 date "1993-05-01" @default.
• W1991002006 modified "2023-09-27" @default.
• W1991002006 title "Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II" @default.
• W1991002006 cites W1481699366 @default.
• W1991002006 cites W1526379338 @default.
• W1991002006 cites W1546404670 @default.
• W1991002006 cites W1555798239 @default.
• W1991002006 cites W1572770561 @default.
• W1991002006 cites W1592664042 @default.
• W1991002006 cites W1660272883 @default.
• W1991002006 cites W1754065147 @default.
• W1991002006 cites W1971950332 @default.
• W1991002006 cites W1972562299 @default.
• W1991002006 cites W1973416721 @default.
• W1991002006 cites W1986621896 @default.
• W1991002006 cites W1987382221 @default.
• W1991002006 cites W1988613599 @default.
• W1991002006 cites W1998840712 @default.
• W1991002006 cites W2033553519 @default.
• W1991002006 cites W2040785900 @default.
• W1991002006 cites W2042367294 @default.
• W1991002006 cites W2057490489 @default.
• W1991002006 cites W2075749214 @default.
• W1991002006 cites W2077077811 @default.
• W1991002006 cites W2081515677 @default.
• W1991002006 cites W2102345056 @default.
• W1991002006 cites W2103246151 @default.
• W1991002006 cites W2103681475 @default.
• W1991002006 cites W2134793597 @default.
• W1991002006 cites W2322795250 @default.
• W1991002006 cites W2504070894 @default.
• W1991002006 cites W4241531133 @default.
• W1991002006 cites W4253200398 @default.
• W1991002006 cites W4294216491 @default.
• W1991002006 doi "https://doi.org/10.1002/jcp.1041550224" @default.
• W1991002006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8097746" @default.
• W1991002006 hasPublicationYear "1993" @default.
• W1991002006 type Work @default.
• W1991002006 sameAs 1991002006 @default.
• W1991002006 citedByCount "18" @default.
• W1991002006 countsByYear W19910020062013 @default.
• W1991002006 crossrefType "journal-article" @default.
• W1991002006 hasAuthorship W1991002006A5004950254 @default.
• W1991002006 hasAuthorship W1991002006A5008349599 @default.
• W1991002006 hasAuthorship W1991002006A5030334751 @default.
• W1991002006 hasAuthorship W1991002006A5053438858 @default.
• W1991002006 hasAuthorship W1991002006A5056573254 @default.
• W1991002006 hasConcept C114851261 @default.
• W1991002006 hasConcept C133936738 @default.
• W1991002006 hasConcept C147897179 @default.
• W1991002006 hasConcept C153911025 @default.
• W1991002006 hasConcept C202751555 @default.
• W1991002006 hasConcept C203014093 @default.
• W1991002006 hasConcept C2776027055 @default.
• W1991002006 hasConcept C2776694085 @default.
• W1991002006 hasConcept C2777132456 @default.
• W1991002006 hasConcept C2778119113 @default.
• W1991002006 hasConcept C2778461978 @default.
• W1991002006 hasConcept C2778616834 @default.
• W1991002006 hasConcept C2778707650 @default.
• W1991002006 hasConcept C2778707968 @default.
• W1991002006 hasConcept C2780923524 @default.
• W1991002006 hasConcept C2781021840 @default.
• W1991002006 hasConcept C2781303535 @default.
• W1991002006 hasConcept C54355233 @default.
• W1991002006 hasConcept C552990157 @default.
• W1991002006 hasConcept C55493867 @default.
• W1991002006 hasConcept C81885089 @default.
• W1991002006 hasConcept C86803240 @default.
• W1991002006 hasConcept C89423630 @default.
• W1991002006 hasConceptScore W1991002006C114851261 @default.
• W1991002006 hasConceptScore W1991002006C133936738 @default.
• W1991002006 hasConceptScore W1991002006C147897179 @default.
• W1991002006 hasConceptScore W1991002006C153911025 @default.
• W1991002006 hasConceptScore W1991002006C202751555 @default.
• W1991002006 hasConceptScore W1991002006C203014093 @default.
• W1991002006 hasConceptScore W1991002006C2776027055 @default.
• W1991002006 hasConceptScore W1991002006C2776694085 @default.
• W1991002006 hasConceptScore W1991002006C2777132456 @default.
• W1991002006 hasConceptScore W1991002006C2778119113 @default.
• W1991002006 hasConceptScore W1991002006C2778461978 @default.
• W1991002006 hasConceptScore W1991002006C2778616834 @default.
• W1991002006 hasConceptScore W1991002006C2778707650 @default.
• W1991002006 hasConceptScore W1991002006C2778707968 @default.
• W1991002006 hasConceptScore W1991002006C2780923524 @default.
• W1991002006 hasConceptScore W1991002006C2781021840 @default.
• W1991002006 hasConceptScore W1991002006C2781303535 @default.
• W1991002006 hasConceptScore W1991002006C54355233 @default.
• W1991002006 hasConceptScore W1991002006C552990157 @default.
• W1991002006 hasConceptScore W1991002006C55493867 @default.
• W1991002006 hasConceptScore W1991002006C81885089 @default.

• next